Cardiff Oncology Inc (CRDF)

$2.19 +0.09 (4.29%)
Market Cap 145.69M
Revenue (ttm) 680,000.00
Net Income (ttm) -45.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,680.88%
Debt to Equity Ratio 0.00
Volume 1,357,700
Avg Vol 1,752,412
Day's Range N/A - N/A
Shares Out 66.53M
Stochastic %K 92%
Beta 1.62
Analysts Strong Sell
Price Target $10.50

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 5 at 3:28 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CRDF Current Share Price: $2.19 Contracts: $CRDF January 15, 2027 $5 Calls Scale in: $1.35- $1.65 Scale out: $2.10-$2.70 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
User123321
User123321 Oct. 5 at 12:22 AM
$CRDF Thanks for reposting frogman’s post. I’m sure he and T also known as Todd from Yahoo appreciate it. 😀 My take is the data and any partnership will do the talking. Hopefully it’s enough to overcome the buffoonery in the C-Suite.
0 · Reply
DCRMIA
DCRMIA Oct. 4 at 9:32 PM
$CRDF 📈🚀👀
0 · Reply
BullRun4
BullRun4 Oct. 4 at 2:02 PM
$CRDF https://www.linkedin.com/posts/linkedhealth-innovations_oncology-biotech-investorevent-activity-7379658855032696832-vGP6?utm_medium=ios_app&rcm=ACoAAAPZvKEBMr9oVTfqP2LL2Wm-6no5eI4XoJU&utm_source=screenshot_social_share&utm_campaign=copy_link
0 · Reply
BullRun4
BullRun4 Oct. 4 at 1:23 AM
$CRDF Onvansertib targets PLK1, a key mitotic kinase and metabolic reprogramming hub in RAS-mutant tumors. This supports broad applicability (G12D, G12V, NRAS, etc.) vs. niche KRAS G12C inhibitors (Lumakras, Krazati). With scans q8 weeks and enrollment complete, PFS and DoR curves should mature meaningfully by Dec 2025–Feb 2026. High CR rate in KRAS-mutant is unprecedented vs SOC. Median DoR ≥ 12 mo would be a significant differentiator vs. SoC (~5–6 mo typical), and CR count reaching 10–12 would strongly reinforce biological effect. There’s real scientific heft behind PLK1 inhibition as a therapeutic strategy — not only cell-cycle arrest but metabolic reprogramming that plausibly explains deepening and durable clinical responses. The preclinical and translational package is stronger than most Phase-2-era programs and the randomized Phase-2 clinical signal (CRs in the drug arm vs none in control) already materially de-risks the biology.
1 · Reply
DCRMIA
DCRMIA Oct. 3 at 2:49 PM
$CRDF one day, sooner than later, CRDF will skyrocket . Hype up!🚀📈🇺🇸
0 · Reply
Gypsygirl2
Gypsygirl2 Oct. 3 at 2:38 PM
$CRDF If you’re here for a quick flip? Keep on going’ but one day news will hit and this will imo open up above $70 or higher. Too many things on the burner with this co that you can’t ignore. All have peace in your heart!
1 · Reply
look2theblue
look2theblue Oct. 3 at 1:57 PM
$CRDF Best for this to creep up slowly as people unfamiliar figure out what's coming. Makes for better FOMO later. Hopefully this caps out around 2-3% at most into the weekend close.
0 · Reply
mark31
mark31 Oct. 3 at 1:42 PM
$CRDF early here no rush
1 · Reply
BullRun4
BullRun4 Oct. 3 at 1:15 PM
$CRDF buy it on sale for $2.12, it should be valued at $7 today. This is a bargain at $2
1 · Reply
Latest News on CRDF
Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Oct 2, 2025, 4:05 PM EDT - 2 days ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 5 weeks ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Jul 30, 2025, 3:27 PM EDT - 2 months ago

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Cardiff Oncology: Data Update Resolves Some Signals

Jul 30, 2025, 11:32 AM EDT - 2 months ago

Cardiff Oncology: Data Update Resolves Some Signals

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jul 29, 2025, 4:07 PM EDT - 2 months ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 27, 2025, 8:30 AM EDT - 3 months ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 3 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 17, 2025, 4:05 PM EDT - 3 months ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Jun 2, 2025, 4:05 PM EDT - 4 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 14, 2025, 9:05 AM EDT - 5 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 5 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

May 2, 2025, 3:35 AM EDT - 5 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 23, 2025, 4:05 PM EDT - 5 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:10 PM EDT - 6 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Apr 15, 2025, 4:05 PM EDT - 6 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:10 PM EST - 7 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 7 months ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 7 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 20, 2025, 4:05 PM EST - 8 months ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Feb 18, 2025, 9:19 AM EST - 8 months ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

Dec 14, 2024, 9:00 AM EST - 10 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 12, 2024, 5:38 AM EST - 10 months ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 5:05 PM EST - 10 months ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 7:20 AM EST - 10 months ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Dec 10, 2024, 6:00 AM EST - 10 months ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 4, 2024, 1:10 PM EDT - 1 year ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 8, 2024, 7:37 PM EST - 1 year ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 6, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 8:06 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:07 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:06 PM EST - 1 year ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 29, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Feb 22, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Jan 17, 2024, 10:30 AM EST - 1 year ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 9:11 PM EDT - 2 years ago

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

Sep 27, 2023, 5:56 AM EDT - 2 years ago

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

COST MLKN PRGS TRUE

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 5 at 3:28 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CRDF Current Share Price: $2.19 Contracts: $CRDF January 15, 2027 $5 Calls Scale in: $1.35- $1.65 Scale out: $2.10-$2.70 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
User123321
User123321 Oct. 5 at 12:22 AM
$CRDF Thanks for reposting frogman’s post. I’m sure he and T also known as Todd from Yahoo appreciate it. 😀 My take is the data and any partnership will do the talking. Hopefully it’s enough to overcome the buffoonery in the C-Suite.
0 · Reply
DCRMIA
DCRMIA Oct. 4 at 9:32 PM
$CRDF 📈🚀👀
0 · Reply
BullRun4
BullRun4 Oct. 4 at 2:02 PM
$CRDF https://www.linkedin.com/posts/linkedhealth-innovations_oncology-biotech-investorevent-activity-7379658855032696832-vGP6?utm_medium=ios_app&rcm=ACoAAAPZvKEBMr9oVTfqP2LL2Wm-6no5eI4XoJU&utm_source=screenshot_social_share&utm_campaign=copy_link
0 · Reply
BullRun4
BullRun4 Oct. 4 at 1:23 AM
$CRDF Onvansertib targets PLK1, a key mitotic kinase and metabolic reprogramming hub in RAS-mutant tumors. This supports broad applicability (G12D, G12V, NRAS, etc.) vs. niche KRAS G12C inhibitors (Lumakras, Krazati). With scans q8 weeks and enrollment complete, PFS and DoR curves should mature meaningfully by Dec 2025–Feb 2026. High CR rate in KRAS-mutant is unprecedented vs SOC. Median DoR ≥ 12 mo would be a significant differentiator vs. SoC (~5–6 mo typical), and CR count reaching 10–12 would strongly reinforce biological effect. There’s real scientific heft behind PLK1 inhibition as a therapeutic strategy — not only cell-cycle arrest but metabolic reprogramming that plausibly explains deepening and durable clinical responses. The preclinical and translational package is stronger than most Phase-2-era programs and the randomized Phase-2 clinical signal (CRs in the drug arm vs none in control) already materially de-risks the biology.
1 · Reply
DCRMIA
DCRMIA Oct. 3 at 2:49 PM
$CRDF one day, sooner than later, CRDF will skyrocket . Hype up!🚀📈🇺🇸
0 · Reply
Gypsygirl2
Gypsygirl2 Oct. 3 at 2:38 PM
$CRDF If you’re here for a quick flip? Keep on going’ but one day news will hit and this will imo open up above $70 or higher. Too many things on the burner with this co that you can’t ignore. All have peace in your heart!
1 · Reply
look2theblue
look2theblue Oct. 3 at 1:57 PM
$CRDF Best for this to creep up slowly as people unfamiliar figure out what's coming. Makes for better FOMO later. Hopefully this caps out around 2-3% at most into the weekend close.
0 · Reply
mark31
mark31 Oct. 3 at 1:42 PM
$CRDF early here no rush
1 · Reply
BullRun4
BullRun4 Oct. 3 at 1:15 PM
$CRDF buy it on sale for $2.12, it should be valued at $7 today. This is a bargain at $2
1 · Reply
McGinvests
McGinvests Oct. 3 at 4:31 AM
$CRDF Who is ready to hear Erlander take a lot of time to say nothing
2 · Reply
Cutlass
Cutlass Oct. 2 at 9:33 PM
$CRDF Well let's see where this goes the next few months - cautiously optimistic that they are starting the road shows off in early October 📋⏳🔎
1 · Reply
mark31
mark31 Oct. 2 at 8:26 PM
$CRDF
1 · Reply
Cutlass
Cutlass Oct. 2 at 8:06 PM
$CRDF Two-Fer = SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc.(CRDF) , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025. Details of the events can be found below. Piper Sandler Virtual Oncology Symposium Format: Fireside Chat Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO) Date: 10/09/2025 Time: 1:00 PM ET Contact Piper Sandler for information on attending the conference. Noble Capital Markets’ Emerging Growth Virtual Equity Conference Format: Fireside Chat Presenter: Mark Erlander, CEO Date: 10/09/2025 Time: 2:00 PM ET
0 · Reply
Channelchek
Channelchek Oct. 2 at 4:43 PM
We're excited to feature Cardiff Oncology ($CRDF) as a participating company at the Noble Capital Markets Emerging Growth Virtual Equity Conference, October 8-9. Don't miss the chance to explore unique investment opportunities. 1x1 Meetings available for qualified investors. 📅 Register: https://www.meetmax.com/sched/event_125441/investor_reg_new.html?attendee_role_id=NOBLE_INVESTOR #NobleConference #EmergingGrowth #InvestorEvent #CardiffOncology
0 · Reply
BillionDollarDreams
BillionDollarDreams Oct. 2 at 12:56 PM
$SPY $BULL $APLD $CRDF Let's go!! 😁 Green af today!
0 · Reply
PSDL75
PSDL75 Oct. 2 at 10:19 AM
$CRDF
0 · Reply
Oknrv
Oknrv Oct. 2 at 1:47 AM
$CRDF Price flat. On balance Volume creeping up.
0 · Reply
look2theblue
look2theblue Oct. 1 at 11:45 PM
$CRDF the bat signal is sneaking through... A move higher is coming.
0 · Reply
BullRun4
BullRun4 Oct. 1 at 10:26 PM
$CRDF very quiet lately! Not much said!!
2 · Reply
mark31
mark31 Oct. 1 at 2:46 PM
$CRDF nice volume
1 · Reply
mark31
mark31 Oct. 1 at 2:08 PM
$CRDF no rush
0 · Reply